SYGNIS : announces outcome of Annual General Meeting 2018

PRESS RELEASE 06 July 2018

SYGNIS AG announces outcome of Annual General Meeting 2018

Shareholders approve all management proposals

Heidelberg, Germany and Cambridge, UK, 06 July 2018 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Annual General Meeting (AGM) held in Heidelberg yesterday, July 05, 2018, approved all management proposals. The participating shareholders represented 38.14% of the total share capital of about 50.37 million shares; all proposals were carried with a minimum Yes vote of 98.3% of the votes present.

"We have continued shaping the organisation positioning ourselves as an enabler of exciting advances in medical science and patient care through careful execution of our 'Grow, Buy and Build' strategy and are now starting to see the benefits of the highly attractive and integrated product and technology portfolio we have been building. This has been driven by our focus on innovation, organic growth as well as a number of successful acquisitions which have been fully integrated within the Group. We see real additional value for our customers and investors. The expansion of our portfolio with complementary products and technologies in conjunction with the continued investment and expansion of our sales & marketing team alongside focussed investment in core research and development programs is expected to continue driving our organic revenue growth and with that increased profitability," said Dr. Heikki Lanckriet, CEO and CSO of SYGNIS. "The change of our name to Expedeon AG aligns the corporate face of the Company with our customer facing brands where we continue to establish ourselves as a leading solutions provider in the genomics, proteomics and immunology markets. We continue to focus on long-term, sustainable success. The strong support at yesterday's Annual General Meeting gives us great confidence for the coming months and years, reaffirming that we are on the right track."

The AGM approved the discharge of the members of the Supervisory Board and the Management Board for fiscal year 2017 and the appointment of Ernst & Young, Mannheim, Germany as auditors for fiscal year 2018.

The AGM resolved an amendment of the resolutions of the AGM 2017 regarding the Stock Option Plan 2017 and the creation of a new conditional capital (Conditional Capital 2018/I) for the fulfilment of the stock option plan and the related amendment to the Articles of Association. The meeting also approved the (partial) cancellation of the Conditional Capital IV.

Furthermore, the AGM resolved the cancellation of the authorization to issue convertible bonds and to exclude subscription rights in accordance with the resolutions of the AGM 2016 and a new authorization to issue convertible bonds, bonds with warrants and profit participation rights with or without conversion or subscription rights and to exclude subscription rights.

The AGM resolved the partial cancellation of the Conditional Capital V, the creation of the Conditional Capital 2018/II and the related amendment to the Articles of Association. Additionally, the AGM approved the cancellation of the Authorized Capital 2017 and the creation of a new authorized capital in the amount of EUR 25,561,278 (Authorized Capital 2018). The meeting authorized the Management Board to exclude subscription rights of shareholders with the consent of the Supervisory Board and the related amendment to the Articles of Association.

Finally, the AGM resolved the change of the Company name to Expedeon AG and the related amendment to the Articles of Association.

The AGM voting results for each agenda item will be published today in theInvestors section ofSYGNIS' website.

For further information, please contact:

SYGNIS AG

Dr. Heikki Lanckriet CEO/CSO

Phone: +44 1223 873 364

Email:heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)

Dr. Claudia Gutjahr-Loeser

Managing Director

Phone: +49 89 210228 0 Email:sygnis@mc-services.eu

About SYGNIS AG:www.sygnis.com

SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group's cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon brand. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###